The c-myc gene is among the most frequent sites of mutation for any oncogene in human cancer. Approximately 15 percent of all cancers exhibit amplification of the c-myc gene and about 25 percent of breast cancers have similar mutations. Chromosomal translocations at c-myc occur in 100 percent of Burkitt's lymphomas, as well as in the related mouse plasmacytomas. Although these gross chromosomal abnormalities have been recognized for many years, it has only recently become apparent that missense mutations can also play a major role in the oncogenic activity of c-myc, and more that 60 percent of Burkitt's and AIDS- associated lymphomas have mutations that alter the protein structure of the already translocated c-myc gene. A major question confronting the c-myc field (and nuclear oncogenes in general) is which cellular genes are targeted ty the oncoprotein to mediate its function in cell cycle progression or apoptosis. Of broader interest is how the c-myc signaling pathway is interwoven with the signals emanating from other oncogenes. The specific goals of this project are to: 1) Dissect the role of the c-Myc protein in signaling pathways leading to cell growth or apoptosis. They will use novel cell lines that are completely deficient in endogenous c-Myc protein expression through the knockout of both chromosomal alleles. The role of phosphorylation in c-Myc activity and the function of a newly isolated Myc-interacting factor, TIP49, will also be investigated. 2) Analyze the Myc-dependent expression of previously identified as well as novel target genes. Novel targets that are linked to specific biological activities of c-Myc will be selected for by subtractive or differential display approaches. 3) Determine the functional role of mutations in the N-terminal domain of the c-Myc oncoprotein that are found in the majority of Burkitt's lymphomas. Cell lines that are reconstituted with only mutant or wt c-Myc protein expression will allow the unambiguous analysis of different functions. The relative activity of different c-Myc mutants in both B cells and fibroblasts will be analyzed.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA080320-03
Application #
6342147
Study Section
Pathology B Study Section (PTHB)
Program Officer
Mufson, R Allan
Project Start
1999-01-01
Project End
2003-12-31
Budget Start
2001-01-01
Budget End
2001-12-31
Support Year
3
Fiscal Year
2001
Total Cost
$297,755
Indirect Cost
Name
Princeton University
Department
Biochemistry
Type
Schools of Arts and Sciences
DUNS #
002484665
City
Princeton
State
NJ
Country
United States
Zip Code
08544
Weyburne, Emily S; Wilkins, Owen M; Sha, Zhe et al. (2017) Inhibition of the Proteasome ?2 Site Sensitizes Triple-Negative Breast Cancer Cells to ?5 Inhibitors and Suppresses Nrf1 Activation. Cell Chem Biol 24:218-230
Posternak, Valeriya; Ung, Matthew H; Cheng, Chao et al. (2017) MYC Mediates mRNA Cap Methylation of Canonical Wnt/?-Catenin Signaling Transcripts By Recruiting CDK7 and RNA Methyltransferase. Mol Cancer Res 15:213-224
Wyszynski, Asaf; Hong, Chi-Chen; Lam, Kristin et al. (2016) An intergenic risk locus containing an enhancer deletion in 2q35 modulates breast cancer risk by deregulating IGFBP5 expression. Hum Mol Genet 25:3863-3876
Pattison, Jillian M; Posternak, Valeriya; Cole, Michael D (2016) Transcription Factor KLF5 Binds a Cyclin E1 Polymorphic Intronic Enhancer to Confer Increased Bladder Cancer Risk. Mol Cancer Res 14:1078-1086
Pattison, Jillian M; Wright, Jason B; Cole, Michael D (2015) Retroviruses hijack chromatin loops to drive oncogene expression and highlight the chromatin architecture around proto-oncogenic loci. PLoS One 10:e0120256
Cowling, V H; Turner, S A; Cole, M D (2014) Burkitt's lymphoma-associated c-Myc mutations converge on a dramatically altered target gene response and implicate Nol5a/Nop56 in oncogenesis. Oncogene 33:3519-27
Hu, Ting; Pan, Qinxin; Andrew, Angeline S et al. (2014) Functional genomics annotation of a statistical epistasis network associated with bladder cancer susceptibility. BioData Min 7:5
Cole, Michael D (2014) MYC association with cancer risk and a new model of MYC-mediated repression. Cold Spring Harb Perspect Med 4:a014316
Schmucker, Adam C; Wright, Jason B; Cole, Michael D et al. (2012) Distal interleukin-1? (IL-1?) response element of human matrix metalloproteinase-13 (MMP-13) binds activator protein 1 (AP-1) transcription factors and regulates gene expression. J Biol Chem 287:1189-97
Cowper-Sal lari, Richard; Zhang, Xiaoyang; Wright, Jason B et al. (2012) Breast cancer risk-associated SNPs modulate the affinity of chromatin for FOXA1 and alter gene expression. Nat Genet 44:1191-8

Showing the most recent 10 out of 19 publications